BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1802 related articles for article (PubMed ID: 32461349)

  • 1. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells.
    Kamei M; Matsuo K; Yoshida Y; Shimada K; Otsuki M; Fujimoto N; Ishibashi M; Quan YS; Kamiyama F; Hara Y; Takamura S; Nakayama T
    Int J Cancer; 2024 Jun; 154(12):2176-2188. PubMed ID: 38346928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer.
    Przewoznik M; Hömberg N; Naujoks M; Pötzl J; Münchmeier N; Brenner CD; Anz D; Bourquin C; Nelson PJ; Röcken M; Mocikat R
    J Immunother; 2012 Apr; 35(3):217-22. PubMed ID: 22421939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXC chemokine ligand (CXCL) 9 and CXCL10 are antagonistic costimulation molecules during the priming of alloreactive T cell effectors.
    Rosenblum JM; Shimoda N; Schenk AD; Zhang H; Kish DD; Keslar K; Farber JM; Fairchild RL
    J Immunol; 2010 Apr; 184(7):3450-60. PubMed ID: 20194716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOD2 regulates CXCR3-dependent CD8+ T cell accumulation in intestinal tissues with acute injury.
    Wu X; Lahiri A; Haines GK; Flavell RA; Abraham C
    J Immunol; 2014 Apr; 192(7):3409-18. PubMed ID: 24591373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
    Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G
    Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.
    Dengel LT; Norrod AG; Gregory BL; Clancy-Thompson E; Burdick MD; Strieter RM; Slingluff CL; Mullins DW
    J Immunother; 2010; 33(9):965-74. PubMed ID: 20948440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
    Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
    J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.
    Zhang J; Zhou Z; Wang C; Shen J; Zheng Y; Zhang L; Wang J; Xia D
    Cancer Immunol Immunother; 2011 Apr; 60(4):559-73. PubMed ID: 21240488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
    Guo S; Smeltz RB; Nanajian A; Heller R
    Front Immunol; 2020; 11():614667. PubMed ID: 33628206
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Chen K; Wu Z; Zhao H; Wang Y; Ge Y; Wang D; Li Z; An C; Liu Y; Wang F; Bi X; Wang H; Cai J; Ma C; Qu C
    Cancer Immunol Res; 2020 Jan; 8(1):81-93. PubMed ID: 31666238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment.
    Wong JL; Berk E; Edwards RP; Kalinski P
    Cancer Res; 2013 Aug; 73(15):4653-62. PubMed ID: 23761327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
    Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P
    Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus-Derived Vectors Fosters Dendritic Cell-Mediated T-cell Cross-Priming.
    Sánchez-Paulete AR; Teijeira Á; Quetglas JI; Rodríguez-Ruiz ME; Sánchez-Arráez Á; Labiano S; Etxeberria I; Azpilikueta A; Bolaños E; Ballesteros-Briones MC; Casares N; Quezada SA; Berraondo P; Sancho D; Smerdou C; Melero I
    Cancer Res; 2018 Dec; 78(23):6643-6654. PubMed ID: 30297531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.
    Guo Y; Luan L; Rabacal W; Bohannon JK; Fensterheim BA; Hernandez A; Sherwood ER
    J Immunol; 2015 Sep; 195(5):2353-64. PubMed ID: 26216888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8
    Matsuo K; Kitahata K; Kawabata F; Kamei M; Hara Y; Takamura S; Oiso N; Kawada A; Yoshie O; Nakayama T
    Front Immunol; 2018; 9():2775. PubMed ID: 30542351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8
    Gardner A; de Mingo Pulido Á; Hänggi K; Bazargan S; Onimus A; Kasprzak A; Conejo-Garcia JR; Rejniak KA; Ruffell B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34987021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.
    Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B
    J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.
    Chenoweth MJ; Mian MF; Barra NG; Alain T; Sonenberg N; Bramson J; Lichty BD; Richards CD; Ma A; Ashkar AA
    J Immunol; 2012 May; 188(9):4149-57. PubMed ID: 22447977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 91.